Key Metrics and Considerations when Evaluating HealthTech Startups

June 19, 2024

The HealthTech landscape is rapidly evolving, driven by technological advancements and an increasing demand for innovative healthcare solutions. From digital health platforms and wearable devices to AI-driven diagnostics and personalized medicine, the HealthTech sector is poised to transform how we approach patient care, disease management, and overall health outcomes. Amidst this dynamic environment, identifying promising investment opportunities is crucial for investors looking to capitalize on the growth potential of HealthTech startups.


However, evaluating HealthTech startups requires more than a cursory glance at their product offerings or market potential. It necessitates a comprehensive understanding of key metrics and considerations that can drive the success and sustainability of these ventures. This article aims to provide a robust framework for evaluating HealthTech startups, enabling investors and academics to make informed decisions and maximize their returns in this fast-paced industry.


Financial Metrics: Assessing Growth and Sustainability


Revenue Growth

Revenue growth is a critical indicator of a HealthTech startup's ability to capture market demand and successfully acquire and retain customers. Sustained revenue growth signifies that the startup's products or services are resonating with the target market and that there is ongoing interest and adoption among users.


When evaluating revenue growth, investors should look at year-over-year growth rates to understand the trajectory of the startup's financial performance. It’s essential to identify the key drivers of revenue, such as the launch of new products, expansion into new markets, or the effectiveness of marketing strategies. A healthy revenue growth rate indicates robust market demand and successful customer acquisition strategies.


Burn Rate

Burn rate measures the rate at which a startup consumes its cash reserves to fund operations. It is a crucial metric for early-stage startups, as it provides insights into the company's financial health and its ability to sustain operations until it becomes profitable or secures additional funding.


A high burn rate might be acceptable in the early stages of a startup, especially if it is investing heavily in product development and market expansion. However, this should be balanced with a clear path to profitability or sustainable funding. Investors should assess the startup's cash runway, which indicates how long the company can continue to operate at its current burn rate without needing additional capital. A well-managed burn rate, coupled with strategic financial planning, is essential for the startup's long-term viability.


Customer Acquisition Costs (CAC)

Customer Acquisition Costs (CAC) represent the cost associated with acquiring a new customer, including expenses on marketing, sales, and other related activities. CAC is a vital metric for evaluating the efficiency of a startup's marketing and sales efforts.


A low CAC relative to the lifetime value of a customer (LTV) is generally desirable, as it indicates a sustainable and scalable business model. LTV represents the total revenue that a business can expect to generate from a customer over the entire duration of their relationship. Comparing CAC to LTV helps investors understand whether the startup can generate sufficient revenue from its customers to cover the costs of acquiring them and drive profitability.


A sustainable business model typically features a CAC that is significantly lower than the LTV, ensuring that the startup can maintain growth without exhausting its financial resources. Investors should scrutinize the startup’s strategies for reducing CAC and improving customer retention to ensure long-term success.


By focusing on these financial metrics, investors can gain a comprehensive understanding of a HealthTech startup’s growth and sustainability. These insights are critical for making informed investment decisions and supporting startups that are well-positioned for long-term success in the competitive HealthTech landscape.


Product Metrics: Assessing User Engagement and Clinical Outcomes


User Engagement Metrics

User engagement metrics are critical for understanding how effectively a HealthTech product resonates with its users and its potential for long-term adoption. These metrics provide insights into the product’s stickiness and user satisfaction, which are crucial for sustained growth.


Key Metrics:

  • Active User Counts: The number of unique users who engage with the product over a specific period (daily, weekly, or monthly). High active user counts indicate strong user interest and product relevance.


  • Session Lengths: The average duration of user sessions. Longer session lengths suggest that users find value in the product and are engaging with its features extensively.


  • Retention Rates: The percentage of users who continue to use the product over time. High retention rates are a strong indicator of user satisfaction and product stickiness.


Importance of User Engagement: User engagement metrics help investors gauge the product's ability to attract and retain users. Consistent engagement is a sign that the product is effectively addressing user needs and has the potential to become an integral part of the users' healthcare routines. High engagement and retention rates are indicative of a product that can achieve long-term adoption and generate sustained revenue.


Clinical Outcomes

For HealthTech startups focused on clinical applications, demonstrating positive clinical outcomes is paramount. These metrics provide evidence of the product’s effectiveness in improving patient health, reducing healthcare costs, and increasing treatment adherence.


Key Metrics:

  • Improved Patient Outcomes: Measures such as reduced symptom severity, improved quality of life, or increased recovery rates. These metrics demonstrate the direct impact of the product on patient health.


  • Reduced Healthcare Costs: Indicators like fewer hospital readmissions, reduced emergency room visits, or decreased medication costs. Cost savings highlight the product’s value proposition to healthcare providers and payers.


  • Increased Treatment Adherence: Metrics showing higher rates of patients following prescribed treatment plans. Increased adherence leads to better health outcomes and more efficient use of healthcare resources.


Demonstrating Clinical Outcomes: HealthTech startups must substantiate their claims of improved clinical outcomes through rigorous studies and data analysis. Clinical trials, pilot studies, and real-world evidence are crucial for validating the product's efficacy. Startups should be able to present compelling data that shows measurable improvements in patient health and economic benefits for the healthcare system.


Regulatory Approvals and Certifications

Regulatory approvals and certifications are critical milestones for HealthTech startups, significantly impacting their ability to commercialize products and gain market acceptance.


Impact of Regulatory Strategy: A robust regulatory strategy is essential for navigating the complex and evolving landscape of healthcare regulations. Successfully obtaining regulatory approvals or clearances, such as FDA approval in the United States or CE marking in Europe, enhances the startup’s credibility and marketability.


Progress in Obtaining Approvals: Investors should assess the startup’s progress in securing 

necessary regulatory approvals. This includes understanding the timeline for approval, the challenges involved, and the strategies employed to address regulatory requirements. Early engagement with regulatory bodies and thorough compliance with guidelines can expedite the approval process and reduce potential delays.


By evaluating user engagement, clinical outcomes, and regulatory approvals, investors can gain a comprehensive understanding of a HealthTech startup’s product viability and market potential. These product metrics are crucial for identifying startups that not only develop innovative solutions but also demonstrate the ability to achieve widespread adoption and deliver tangible health benefits.


Market Metrics: Assessing Opportunity and Competition


Addressable Market Size

The size of the addressable market is a fundamental metric for evaluating the potential revenue and growth opportunities for HealthTech startups. A large and growing market indicates a higher potential for substantial returns on investment.


Importance of Market Size:

  • Revenue Potential: A larger addressable market provides more opportunities for revenue generation. It signifies that there is a substantial customer base that can be tapped into.


  • Growth Opportunities: Understanding the market size helps in identifying potential for future growth and expansion. It indicates the scale at which the startup can grow and the overall impact it can have on the industry.


Analyzing Target Market Segments:

  • Segment Identification: Investors should analyze the specific segments within the broader market that the startup targets. This includes demographics, geographic regions, and specific healthcare needs.


  • Market Expansion Potential: Evaluating the potential for market expansion is crucial. This involves assessing whether the startup can expand into new segments or geographical areas, thus increasing its market reach and revenue opportunities.


Competitive Landscape Analysis

Understanding the competitive landscape is vital for identifying potential threats and assessing the startup’s ability to differentiate itself in the market. A thorough competitive analysis helps in determining the startup's position relative to its competitors and the unique value it brings to the table.


Identifying Potential Threats:

  • Direct Competitors: Identifying direct competitors that offer similar products or services helps in understanding the level of competition in the market.


  • Indirect Competitors: Analyzing indirect competitors that might offer alternative solutions to the same problem is also important.


Differentiation Factors:

  • Proprietary Technology: The startup’s use of proprietary technology can be a significant differentiator. Unique technological advancements can provide a competitive edge and act as a barrier to entry for other players.


  • Intellectual Property: Strong intellectual property (IP) protection, including patents and trademarks, can safeguard the startup’s innovations and provide a sustained competitive advantage.


  • Unique Partnerships: Strategic partnerships with established healthcare providers, research institutions, or technology companies can enhance the startup’s market position and provide access to critical resources and expertise.


Assessing Competitive Advantages:

  • Sustainability of Competitive Edge: Investors should evaluate the sustainability of the startup's competitive advantages. This involves assessing how well the startup can maintain its unique position in the market over time, considering factors such as technological advancements, market trends, and potential new entrants.


  • Adaptability and Innovation: The startup’s ability to adapt to changing market conditions and continuously innovate is crucial for sustaining its competitive edge. Investors should look for a culture of innovation and a proactive approach to market changes.


By analyzing market size and the competitive landscape, investors can gain insights into the overall opportunity and potential challenges that HealthTech startups may face. This comprehensive understanding helps in making informed investment decisions and identifying startups with the potential for long-term success and market leadership.


Notable Labs: A Benchmark for Evaluating HealthTech Startups


Notable Labs exemplifies the successful application of key metrics and considerations in the HealthTech sector. As a clinical-stage platform therapeutics company, Notable Labs leverages advanced AI and machine learning to develop predictive precision medicines. By examining Notable Labs, investors can gain insights into what makes a HealthTech startup promising and worth investing in.


Financial Metrics: Growth and Sustainability

Notable Labs has demonstrated impressive revenue growth driven by the increasing demand for personalized cancer treatments. Their innovative approach to precision medicine has attracted significant funding from prominent venture capital firms, ensuring a solid cash runway. Additionally, their efficient customer acquisition strategy has resulted in a low customer acquisition cost (CAC) relative to the lifetime value of a customer (LTV), indicating a sustainable business model.


Product Metrics: User Engagement and Clinical Outcomes

The success of Notable Labs is largely attributed to its robust user engagement metrics. They have a high count of active users, indicating strong adoption among healthcare providers and patients. Furthermore, Notable Labs has conducted rigorous clinical studies demonstrating improved patient outcomes, including increased treatment efficacy and reduced side effects. These positive clinical outcomes have been pivotal in gaining regulatory approvals and certifications, bolstering their market acceptance and credibility.


Market Metrics: Opportunity and Competition

Notable Labs operates in the rapidly growing market of precision medicine, which is projected to reach substantial market size in the coming years. Their focus on oncology, a segment with significant unmet medical needs, positions them well for future growth and expansion. Notable Labs maintains a competitive edge through its proprietary AI technology and a robust portfolio of intellectual property, including patents that protect their innovative approaches. Strategic partnerships with leading healthcare institutions further enhance their market position.



Qualitative Considerations: Team, Vision, and Execution


The strength and experience of the founding team are critical indicators of a HealthTech startup's potential for success. Investors should prioritize evaluating the domain expertise and track record of the team members. A founding team with a deep understanding of the healthcare sector, combined with technical expertise in their specific area of innovation, significantly increases the likelihood of navigating the complexities of the healthcare industry. This includes understanding regulatory requirements, managing clinical trials, and engaging with healthcare providers and patients. A proven track record in previous ventures or relevant industry experience can also provide assurance that the team has the capability to execute their business plan effectively.


Vision and Execution Plan

A startup’s vision should clearly articulate the problem it aims to solve and the innovative solution it offers. Evaluating the clarity and feasibility of this vision is crucial for determining the startup’s long-term potential. Investors should assess whether the startup's goals are realistic and aligned with market needs.


Equally important is the startup's execution plan. A well-defined execution plan outlines the steps the company will take to achieve its vision, including product development timelines, go-to-market strategies, and milestones for growth. The plan should also address potential challenges and outline contingency strategies. A robust execution plan demonstrates that the startup not only has a compelling vision but also the practical strategies to bring it to fruition.


Successful execution often hinges on the startup's ability to adapt and pivot in response to 

market feedback and changing conditions. This adaptability, combined with a strong vision and execution strategy, forms the backbone of a HealthTech startup’s potential for success.


Conclusion


Evaluating HealthTech startups requires a multifaceted approach that integrates various metrics and considerations. Investors need to assess financial metrics, such as revenue growth, burn rate, and customer acquisition costs, to understand the startup’s financial health and sustainability. Product metrics, including user engagement, clinical outcomes, and regulatory approvals, are essential for gauging the product's market fit and potential for long-term adoption.


Market metrics, such as addressable market size and competitive landscape analysis, provide insights into the startup’s growth opportunities and competitive positioning. Additionally, qualitative considerations like the strength and experience of the founding team, the clarity and feasibility of the startup’s vision, and the robustness of its execution plan are crucial for evaluating the overall potential for success.


Staying updated on emerging trends, regulatory changes, and technological advancements in the HealthTech sector is vital. This ongoing awareness helps investors make informed decisions and adapt to the dynamic landscape of health technology. By leveraging this comprehensive evaluation framework, investors can identify promising investment opportunities in HealthTech and maximize their potential for returns.


Informed decision-making, backed by thorough analysis and a deep understanding of the industry, is key to navigating the complexities of HealthTech investments. By embracing this approach, investors can contribute to the advancement of innovative health technologies that have the potential to transform patient care and improve healthcare outcomes globally.

A nurse is holding a bottle of pills in her hand.

HealthTech Innovations in Chronic Disease Management

July 29, 2024
Discover how HealthTech innovations are transforming chronic disease management. This blog highlights the latest technologies like remote monitoring, AI, and mobile apps, which improve patient care, outcomes, and reduce costs. Explore real-world examples and see how personalized and preventive approaches enhance quality of life for millions.
A female doctor wearing a white coat with a stethoscope around her neck.

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

By Daniel Ferry • July 29, 2024
Notable Labs is a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming months.
A man in a lab coat and mask is holding a box of test tubes.

Notable Labs: Revolutionizing Pediatric Leukemia Treatment

By Syeda Abeer Iqbal • July 29, 2024
Notable Labs is transforming pediatric leukemia treatment with its Predictive Precision Medicines Platform (PPMP), which boasts a 97% predictive precision. This platform rapidly identifies the most effective treatments for individual patients, significantly reducing the time and cost of cancer therapy. Notable Labs focuses on personalized medicine, combining high-throughput screening and machine learning to predict patient responses and tailor treatments accordingly. Their innovative approach has shown promising results in clinical validation studies, offering new hope for improving outcomes in pediatric leukemia.
A man in a lab coat is pushing a cart down a hallway.

Notable Labs' Innovative Approach to Cancer Treatment

By Scott Smith • July 29, 2024
Notable Labs is revolutionizing cancer treatment with its innovative approach to combination therapy, which targets multiple cancer pathways simultaneously. Their Predictive Precision Medicine Platform (PPMP) leverages advanced data analysis and machine learning to identify the most effective drug combinations for individual patients. By using high-throughput screening and bio-simulation, Notable Labs accelerates drug development, reduces costs, and improves clinical trial success rates. This approach promises significant improvements in patient outcomes, particularly for pediatric leukemia, by providing personalized, effective treatments and minimizing side effects.
A woman is laying in a dental chair in a dark room looking up.

Notable Labs Revolutionizing Precision Medicine

By Ayushi Hisaria • July 29, 2024
Notable Labs' cutting-edge diagnostic technology, boasting a 95% prediction accuracy per a Stanford study, is set to revolutionize pediatric leukemia treatment by identifying the most effective therapies. Their mission centers on advancing precision diagnostics to enhance therapy efficacy for young patients. Utilizing high-throughput screening and machine learning, Notable's platform offers tailored treatment plans, significantly improving outcomes for rare and aggressive forms of leukemia. This approach holds promise for personalized medicine, ensuring each child receives optimal, life-saving care.
A woman wearing headphones and a red sweater is stretching her arms in the woods.

How Notable Labs is Revolutionizing Cancer Treatment

By Kathleen Mackay • July 29, 2024
Notable Labs is transforming cancer treatment with its innovative combination therapy approach. By leveraging its Predictive Precision Medicine Platform (PPMP), Notable identifies optimal drug combinations tailored to individual patients. This methodology aims to reduce the development of resistant cancer cells and allows each drug to be used at its best dosage without intolerable side effects. The platform has shown impressive predictive accuracy in clinical trials, particularly for pediatric leukemia. Notable's commitment to precision medicine offers new hope for patients with high unmet medical needs, driving better treatment outcomes and enhancing quality of life.
Two little girls are sitting at a table painting with brushes.

Innovative Diagnostics for Pediatric Leukemia: The Notable Labs Advantage

By Fabian Goguta • July 29, 2024
Notable Labs leverages predictive precision medicine to revolutionize cancer treatment, particularly pediatric leukemia. Their Predictive Medicine Platform (PMP) uses advanced technologies like flow cytometry and machine learning to analyze patient-specific cancer cell responses, offering highly accurate predictions for effective treatments. Clinical validation studies have shown a 97% precision in predicting responders. Collaborations with renowned institutions like Texas Children’s Hospital and UCSF further highlight Notable's commitment to improving pediatric oncology outcomes, making personalized, rapid, and effective cancer treatments a reality.
A woman and a little girl are sitting on the floor.

Precision Medicine in Pediatric Leukemia

By Divya Narasimhan, MSc • July 29, 2024
Precision medicine is revolutionizing pediatric leukemia treatment by offering tailored therapies based on individual genetic profiles. Notable Labs’ predictive precision medicine platform, driven by machine learning, is at the forefront of this transformation. With a 95% accuracy rate, this technology identifies the most effective treatments for rare and aggressive leukemia subtypes, such as pAML and JMML, ensuring better outcomes. This blog explores the advanced technological foundations, life-saving impact, and promising future of Notable Labs' approach in personalized cancer care for children.
A person is holding a baby 's hand on a bed.

Precision Medicine in Childhood Leukemia

By Dr. David Letsa • July 29, 2024
Notable Labs, founded by Matthew De Silva, emerged from his personal quest to find better treatments for glioblastoma after his father's diagnosis. Partnering with Dr. Thomas Bock, De Silva's vision turned into a biotech startup revolutionizing cancer treatment through its Predictive Precision Medicine Platform (PPMP). The company's leadership team includes industry veterans like Dr. Joseph Wagner, Dr. Glenn Michelson, and Scott McPherson. Headquartered in Foster City, California, Notable Labs collaborates with top hospitals and leverages cutting-edge drug screening technology to deliver personalized cancer therapies, significantly improving patient outcomes.
A microscope is sitting on top of a table in a laboratory.

The Promise of Combination Therapy

By Dr. Anjaney Kothari • July 29, 2024
Given the complexity of the biological mechanisms that underlie cancer, it is prudent to identify and target more than one Achilles’ heel to attack this multifactorial disease. This can be achieved by employing combination therapy, an approach to cancer treatment that combines multiple therapeutic agents to improve patient outcomes. Notable Labs is at the forefront of revolutionary advancements in combination therapy, one noteworthy example being its long-standing collaboration with Syros Pharmaceuticals. For Syros, Notable developed a highly efficient predictive biological test to screen patients for the clinical trial of a combination therapy against non-acute promyelocytic leukemia (APL) acute myeloid leukemia (AML). Notable Labs’ innovative approach to combination therapy holds immense promise for significantly improving cancer treatment outcomes despite current limitations in commercial pursuit. This blog dives into the science behind the promise of combination therapy, how Notable is contributing toward the evolution of this technology, and why the company’s Board of Directors is excellently positioned to advance this field in the future. Notable Labs' investigation into combination therapy against cancer is backed by decades of scientific research. Combination therapy holds immense promise in the fight against cancer because of its ability to additively or synergistically target two or more cancer pathways. Due to its multi-target approach, combination therapy is also an effective strategy to overcome anti-cancer drug resistance. By collaborating with Syros in 2017, Notable Labs contributed to the phase II clinical trial of a therapy combining the drugs tamibarotene and azacitidine against non-APL AML. For this multi-arm monotherapy and combination therapy trial, Notable developed a blood-based biomarker test to help predict patient response to treatment. Specifically, Notable was involved in conducting ex vivo experiments on peripheral blood mononuclear cells (PBMCs) isolated from the blood samples of non-APL AML patients. Harnessing the power of high-throughput flow cytometry, these experiments revealed that a 72-hour ex vivo exposure of PBMCs to tamibarotene upregulates various markers of myeloid cell differentiation, including the RARα pathway target CD38. Importantly, treatments that can promote myeloid cell differentiation are known to be effective against some subtypes of AML. Therefore, by testing a patient’s blood sample using Notable’s ex vivo approach, it is possible to predict whether the patient is likely to respond well to tamibarotene in monotherapy and combination therapy. Indeed, Notable’s ex vivo assay became one of the strategies Syros adopted when screening patients for enrolment in the phase II clinical trial of tamibarotene (alone as well as in combination with azacitidine). Market Challenges Currently, cancer treatment – and thus, the oncology market as a whole – is faced with a three-pronged challenge. There are millions of non-responders who are not benefiting from chemotherapeutic drugs, thousands of compelling drugs that need to be shelved because of perceived non-response, and hundreds of promising candidate drugs that are struggling to navigate the drug development pipeline. Notable Labs is committed to resolving these challenges through its successfully tested predictive precision medicine pipeline, a significant application of which was demonstrated during the Syros clinical trial.  Notable Labs’ commitment is also one of the reasons why it has decided not to commercialize the combination therapy technology immediately. Notable wants to focus on refining the technology further, expanding its applications, and ensuring that it integrates seamlessly into existing healthcare systems. The company aims to develop more sophisticated prediction models and address regulatory and logistical challenges. This approach will help make Notable's technology accessible to a broader patient population, maximizing the life-saving potential of predictive diagnostics as well as combination therapy. Broader Applications The high-throughput nature of Notable’s ex vivo flow-cytometry-based predictive precision medicine pipeline has helped identify many powerful drug combinations to treat other cancers such as juvenile myelomonocytic leukemia. This pipeline also has great potential for identifying effective drug combinations and guiding patient enrolment in clinical trials of combination therapies for other cancers, including solid tumors. In the case of solid tumors, the Notable pipeline’s blood samples for ex vivo testing could be replaced by biopsy samples, circulating tumor cells, pleural effusion, or ascites, among other sampling options. Founding Story Notable’s CEO, Dr. Thomas Bock (MD, MBA), has ensured that the company is well-positioned to transform combination therapy for cancer. For decades, our CEO has worked on multiple dimensions of oncology, including precision medicine, prevention of inherited cancers, and cancer vaccines. At Notable, Dr. Bock combines his medical and business training to accomplish the company’s mission of dramatically improving patient outcomes and the success, speed, and cost of developing new medicines. Strength of the Board of Directors Notable’s esteemed Board of Directors boasts of more than 150 years of combined professional experience in premier life science companies. Our board members excel in medicine (Dr. Bock), pharmacology (Mr. Tuomo Pätsi), business (Dr. Bock), finance (Mr. Michael Rice, Mr. Peter Feinberg, Mr. Thomas Graney), media communications (Ms. Michele Galen), and law (Mr. Thomas Dubin), fostering a vibrant and eclectic environment for Notable to thrive. This diverse team of bona fide giants from the pharmaceutical and biotechnology sectors is set to efficiently guide Notable Labs on its path to success in combination therapy and beyond. Conclusion Combination therapy for cancer, aided by predictive methods, could significantly improve patient outcomes while also broadening the population of patients who can benefit from a given drug combination. Leading the charge in this direction, Notable Labs’ predictive precision medicine pipeline boasts of massive potential to not only identify effective drug combinations for combination therapy, but also guide patient enrolment in clinical trials through predictive screening. Moving ahead, Notable’s technology is set to transform the treatment of multiple types of cancer by ensuring positive patient outcomes of personalized combination therapies in shorter times and at lower costs. Additional Data Points AML statistics (American Cancer Society): estimated 20,800 new diagnoses and 11, 220 deaths in the US in 2024. Success stories and collaborations in the field of combination therapy: Notable’s collaboration with Syros to develop a predictive test for patient response to monotherapy and combination therapy. Potential impact on cancer treatment outcomes: Combination therapy, aided by predictive methods, has the potential to enhance patient outcome while also broadening the population of patients who can benefit from a given combination of drugs. Future directions for research and development: AML treatment strategies must pivot towards personalized/precision medicine because of overwhelming heterogeneity of the disease. References Combination therapy in combating cancer . (2017). Oncotarget Notable’s collaboration with Syros . (2017). Notable Labs + Syros Differentiation therapy for myeloid malignancies: beyond cytotoxicity . (2021). Blood Cancer Journal New strategies to treat AML: novel insights into AML survival pathways and combination therapies . (2021). Leukemia Precision oncology using ex vivo technology: a step towards individualised cancer care? . (2022). Expert Reviews in Molecular Medicine Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML . (2023). Blood Advances Notable Labs’ JMML data . (2023). Notable Labs Key statistics for acute myeloid leukemia (AML) . (2024). American Cancer Society About the Author Dr. Anjaney Kothari is a scientific writer and researcher with a decade of experience in biomedical research. He completed his Ph.D. in Biomedical Engineering from Virginia Tech (USA) in 2019, developing and characterizing holistic in vitro and ex vivo models of hepatic and gastrointestinal toxicity. He has since been working as a freelance writer and researcher for companies operating in diverse niches, including biotechnology and biopharmaceuticals. Disclaimer The content of these blogs reflects the research and opinions of the individual authors and does not necessarily represent the views or positions of Notable Labs or its affiliates. The information provided is for educational and informational purposes only and should not be construed as medical, legal, or financial advice. Notable Labs makes no representations as to the accuracy, completeness, or validity of any information in these blogs and will not be liable for any errors, omissions, or any losses, injuries, or damages arising from their use. These blogs may reference third-party research, studies, or resources. Notable Labs does not endorse or assume responsibility for the content or practices of these third parties. Any reliance on the information provided is at the reader's own risk. For biotechnology and pharmaceutical content, note that ongoing research and clinical trials may change the context and results discussed. Always refer to the latest research and guidelines from reputable sources.
More Posts